in10018

Key facts

Mechanism of action

Focal adhesion kinase 1 inhibitor

Primary target: Focal adhesion kinase 1

Approval history

1. 1001 Phase 3 · Biotest Farmaceutica Ltda · Non-severe community-acquired pneumonia (CAP) or moderate or
2. Immune Globulin 10% Intravenous Solution Phase 3 · Vera Therapeutics · Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
3. IN10018 Phase 2 · Hospital Authority · Cervical Adenocarcinoma
4. Recombinant staphylokinase Approved · First People's Hospital · ST Elevation Myocardial Infarction

Frequently asked questions